Theralase Technologies Inc (TLT-X) Stock Price and News - The Globe and Mail

Add to Watchlist Create Alerts

Delayed Last Update

Volume

Day Low0.160

Day High0.165

Open:0.160

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

Automated Summaries - The Globe and Mail

Closing Bell: Theralase Technologies Inc flat on Wednesday (TLT)

AI-generated - The Globe and Mail

Theralase Technologies: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (TLT)

AI-generated - The Globe and Mail

Theralase Technologies: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (TLT)

February 19, 2024

Theralase Release’s 3Q2023 Interim Financial Statements

November 29, 2023

Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement

November 29, 2023

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

November 17, 2023

Theralase(R) Announces Brokered LIFE Financing

October 23, 2023

Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study

October 23, 2023

Theralase(R) Provides Update on Bladder Cancer Clinical Study

October 16, 2023

Theralase(R) Files US Patent for Enhanced Immunotherapy

October 5, 2023

Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)

September 29, 2023

Theralase(R) Grants Stock Options

September 21, 2023

Theralase(R) Closes Private Placement Equity Financing

September 7, 2023

Theralase Release’s 2Q2023 Interim Financial Statements

August 29, 2023

Theralase(R) Closes Non-Brokered Private Placement Equity Financing

Theralase(R) Announces Appointment of New Independent Director

Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements

Theralase(R) Releases 1Q2023 Interim Financial Statements

Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer

Theralase Provides Update on Phase II Bladder Cancer Study

Theralase Expands Intellectual Property Portfolio

Stocks in play: Theralase Technologies Inc.

Theralase® Research - One of the Top 10 Most Downloaded Papers

Theralase® Phase Ib NMIBC Clinical Study Published

Theralase Releases Q122 Interim Financial Statements

Theralase Release FY2021 Audited Financial Statements

Theralase® Provides Update on Phase II Bladder Cancer Clinical Study

Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine

February 7, 2022

Theralase Expands Intellectual Property Portfolio

December 9, 2021

Theralase Releases 3Q21 Financial Statements and Newsletter

November 29, 2021

Theralase Announces Leadership Reorganization

November 15, 2021

Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter

August 30, 2021

Profile

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs,Â in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.